CSIMarket
 

Allakos Inc   (NASDAQ: ALLK)

Allakos Inc 's

Competitiveness




 

ALLK Sales vs. its Competitors Q1 2025



Comparing the current results to its competitors, Allakos Inc reported Revenue decrease in the 1 quarter 2025 year on year by 0 %, despite the revenue increase by the most of its competitors of 2.92 %, recorded in the same quarter.

List of ALLK Competitors





Revenue Growth Comparisons




Net Income Comparison


Allakos Inc recorded a net loss, despite income increase by most of its competitors of 0 %

<<  ALLK Stock Performance Comparisons



*Market share is calculated based on total revenue.

  News about Allakos Inc Contracts

Allakos Reports Promising Phase 1 Results for Subcutaneous AK006 A Breakthrough in Allergy Therapy

October 10, 2024
Allakos Reports Promising Phase 1 Results for Subcutaneous AK006: A Breakthrough in Allergy Therapy In a significant advancement for the treatment of mast cell-related diseases, Allakos Inc. has announced the successful results of its Phase 1 clinical trial assessing the bioavailability and safety of subcutaneously administered AK006 in healthy volunteers. This novel therapeutic candidate targets mast cell activation and has shown considerable promise, setting the stage for its potential application in treating chronic spontaneous urticaria (CSU).The study revealed that AK006 administered via subcutaneous injection exhibited approximately 77% bioavailability, indicating a robust absorption and subsequent eff...





Publicly Traded Peers of Allakos Inc




Abeona Therapeutics Inc
Share Performance



+2.54%
This Year



Abeona Therapeutics Inc
Profile

Abeona Therapeutics Inc is a biopharmaceutical company focused on developing gene and cell therapies for rare genetic diseases. Their business model revolves around identifying and acquiring promising technologies, conducting pre-clinical and clinical research, and eventually bringing these therapies to the market. They collaborate with academic institutions, medical centers, and patient advocacy groups to advance their pipeline and provide solutions for currently untreatable genetic disorders.

More about Abeona Therapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 310.628 mill. $ 30.093 mill. $ -62.887 mill.


Cytodyn inc
Share Performance



-31.03%
This Quarter



Cytodyn inc
Profile

Cytodyn Inc is a biotechnology company that focuses on the development and commercialization of innovative treatments for a range of diseases, including cancer and viral infections. The company primarily generates revenue through the licensing and sale of its therapeutics to medical institutions and pharmaceutical companies. Cytodyn's business model revolves around the research and development of novel drugs, conducting clinical trials, and forming strategic partnerships to bring their innovative treatments to market.

More about Cytodyn inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 257.860 mill. $ - mill. $ -42.699 mill.


Journey Medical Corp
Share Performance



-1.21%
This Year



Journey Medical Corp
Profile

Journey Medical Corporation is a pharmaceutical and medical device company that specializes in developing and commercializing innovative products for dermatology and aesthetics. Their business model revolves around conducting research and development to create new products, acquiring the necessary regulatory approvals, and partnering with healthcare professionals to effectively distribute and market these products. By focusing on dermatology and aesthetics, Journey Medical Corporation aims to address unmet medical needs and provide cutting-edge solutions to improve patient outcomes in these fields.

More about Journey Medical Corp's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 202.354 mill. $ 68.181 mill. $ -6.104 mill.


Evolus Inc
Share Performance



+3.22%
30 Days



Evolus Inc
Profile

Evolus Inc is a pharmaceutical company that operates in the field of aesthetics, with a primary focus on developing and commercializing minimally invasive treatments for patients. Their business model revolves around researching and developing innovative neurotoxin products to address various facial aesthetic concerns. The company aims to bring their products to market through strategic partnerships with healthcare professionals and providers, ensuring widespread accessibility and utilization.

More about Evolus Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 528.751 mill. $ 317.113 mill. $ -34.333 mill.


Esperion Therapeutics Inc
Share Performance



+169.49%
One Year



Esperion Therapeutics Inc
Profile

Esperion Therapeutics Inc's business model focuses on the development and commercialization of innovative therapies for addressing cardiovascular diseases.

More about Esperion Therapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 799.303 mill. $ 418.244 mill. $ -7.423 mill.

98 more competitors available

Sign in to see all competitors

Sources: Allakos Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Allakos Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.